<p>CalciMedica Inc.（納斯達克代碼：CALC - 獲取免費報告）在週二的交易中下跌了 2.1%。該公司的股價最低曾達到 5.55 美元，最後交易價格為 5.73 美元。在午盤交易中，共交易了 44,801 股，較平均交易量 92,307 股下降了 51%。該股票此前收盤價為 5.85 美元。</p>
<h2>華爾街分析師預測增長</h2>
<p>另外，Weiss Ratings 在 10 月 8 日的研究報告中重新發布了對 CalciMedica 股票的 “賣出（d-）” 評級。一位研究分析師給予該股票買入評級，另一位則給予賣出評級。根據 MarketBeat.com 的數據，該股票目前的共識評級為 “持有”，平均目標價格為 16.00 美元。</p>
<p><strong>查看我們關於 CalciMedica 的最新股票報告</strong></p>
<h2>CalciMedica 股票表現</h2>
<p>該公司的債務與股本比率為 1.39，速動比率為 4.04，流動比率為 4.03。該公司的市值為 8256 萬美元，市盈率為-3.54，貝塔係數為 0.58。該公司的 50 日簡單移動平均線為 4.12 美元，200 日簡單移動平均線為 3.24 美元。</p>
<p>CalciMedica（納斯達克代碼：CALC - 獲取免費報告）最近於 11 月 12 日發佈了季度財報。該公司報告本季度每股收益（EPS）為-0.39 美元，超出市場共識預期的-0.41 美元，超出幅度為 0.02 美元。平均而言，賣方分析師預計 CalciMedica Inc.在當前財年將發佈-2.21 美元的每股收益。</p>
<h2>CalciMedica 的機構交易</h2>
<p>大型投資者最近調整了對該股票的持有。Stonehage Fleming Financial Services Holdings Ltd 在第三季度購買了價值 165,000 美元的 CalciMedica 新頭寸。Meritage Portfolio Management 在第三季度將其在 CalciMedica 的持股增加了 33.8%。Meritage Portfolio Management 目前擁有 61,539 股該公司的股票，價值 189,000 美元，此前在此期間又購買了 15,539 股。Sheets Smith Investment Management 在第三季度收購了價值約 157,000 美元的 CalciMedica 新股份。Cetera Investment Advisers 在第二季度將其在 CalciMedica 的股份增加了 33.1%。Cetera Investment Advisers 目前擁有 36,385 股該公司的股票，價值 58,000 美元，此前在此期間又購買了 9,045 股。最後，Sound View Wealth Advisors Group LLC 在第二季度收購了價值約 32,000 美元的 CalciMedica 新頭寸。</p>
<h2>CalciMedica 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>CalciMedica, Inc.（納斯達克代碼：CALC）是一家臨牀階段的生物製藥公司，專注於開發調節鈣介導的炎症通路的療法。公司總部位於伊利諾伊州北布魯克，應用專有的離子通道技術來應對由免疫反應失調引起的嚴重炎症疾病。</p>
<p>該公司的主要產品候選藥物 Auxora™是一種選擇性鈣釋放激活鈣（CRAC）通道抑制劑。Auxora 正在臨牀試驗中評估用於治療與全身性炎症反應綜合症（SIRS）和急性呼吸窘迫綜合症（ARDS）相關的急性胰腺炎，適用於包括 COVID-19 肺炎在內的嚴重肺部疾病患者。</p>
<h2>精選文章</h2>
<ul>
<li>我們更看好的五隻股票比 CalciMedica 更好</li>
<li>請勿刪除，立即閲讀</li>
<li>崩盤已經開始（大多數人只是看不見而已）</li>
<li>警報：在 2026 年 1 月之前拋售這五隻股票！</li>
<li>[無腦黃金投資]：“給我一個更好的投資。”</li>
<li>投資者警報：微型 “3 美元人工智能奇蹟股票” 即將爆發</li>
</ul>
<p><em>此即時新聞警報由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 CalciMedica 嗎？</h2>
<p>在你考慮投資 CalciMedica 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 CalciMedica 並不在名單上。</p>
<p>雖然 CalciMedica 目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

CALC

<p>CalciMedica（納斯達克代碼：CALC）股價下跌 2.1%，至 5.73 美元，交易量較平均水平下降 51%。分析師的評級不一，給出了一項買入和一項賣出，導致共識評級為持有，目標價為 16.00 美元。該公司報告的季度每股收益為-0.39 美元，超出預期。機構投資者增加了持股比例，CalciMedica 專注於炎症性疾病的治療。儘管評級為持有，分析師建議其他股票可能是更好的投資選擇</p>

<p>CalciMedica Inc. (NASDAQ:CALC - Get Free Report) traded down 2.1% during trading on Tuesday . The company traded as low as $5.55 and last traded at $5.73. 44,801 shares were traded during mid-day trading, a decline of 51% from the average session volume of 92,307 shares. The stock had previously closed at $5.85.</p>
<div class="lb-trans"><p>CalciMedica Inc.（納斯達克代碼：CALC - 獲取免費報告）在週二的交易中下跌了 2.1%。該公司的股價最低曾達到 5.55 美元，最後交易價格為 5.73 美元。在午盤交易中，共交易了 44,801 股，較平均交易量 92,307 股下降了 51%。該股票此前收盤價為 5.85 美元。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><p>Separately, Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of CalciMedica in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of &#34;Hold&#34; and an average price target of $16.00.</p>
<div class="lb-trans"><p>另外，Weiss Ratings 在 10 月 8 日的研究報告中重新發布了對 CalciMedica 股票的 “賣出（d-）” 評級。一位研究分析師給予該股票買入評級，另一位則給予賣出評級。根據 MarketBeat.com 的數據，該股票目前的共識評級為 “持有”，平均目標價格為 16.00 美元。</p>
</div><p><strong>Check Out Our Latest Stock Report on CalciMedica</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 CalciMedica 的最新股票報告</strong></p>
</div><h2>CalciMedica Stock Performance</h2>
<div class="lb-trans"><h2>CalciMedica 股票表現</h2>
</div><p>The company has a debt-to-equity ratio of 1.39, a quick ratio of 4.04 and a current ratio of 4.03. The company has a market capitalization of $82.56 million, a price-to-earnings ratio of -3.54 and a beta of 0.58. The firm has a 50-day simple moving average of $4.12 and a two-hundred day simple moving average of $3.24.</p>
<div class="lb-trans"><p>該公司的債務與股本比率為 1.39，速動比率為 4.04，流動比率為 4.03。該公司的市值為 8256 萬美元，市盈率為-3.54，貝塔係數為 0.58。該公司的 50 日簡單移動平均線為 4.12 美元，200 日簡單移動平均線為 3.24 美元。</p>
</div><p>CalciMedica (NASDAQ:CALC - Get Free Report) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.39) EPS for the quarter, beating the consensus estimate of ($0.41) by $0.02. On average, sell-side analysts anticipate that CalciMedica Inc. will post -2.21 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>CalciMedica（納斯達克代碼：CALC - 獲取免費報告）最近於 11 月 12 日發佈了季度財報。該公司報告本季度每股收益（EPS）為-0.39 美元，超出市場共識預期的-0.41 美元，超出幅度為 0.02 美元。平均而言，賣方分析師預計 CalciMedica Inc.在當前財年將發佈-2.21 美元的每股收益。</p>
</div><h2>Institutional Trading of CalciMedica</h2>
<div class="lb-trans"><h2>CalciMedica 的機構交易</h2>
</div><p>Large investors have recently modified their holdings of the stock. Stonehage Fleming Financial Services Holdings Ltd purchased a new position in CalciMedica in the third quarter valued at $165,000. Meritage Portfolio Management increased its holdings in CalciMedica by 33.8% during the 3rd quarter. Meritage Portfolio Management now owns 61,539 shares of the company's stock worth $189,000 after purchasing an additional 15,539 shares during the period. Sheets Smith Investment Management acquired a new stake in CalciMedica in the 3rd quarter valued at about $157,000. Cetera Investment Advisers boosted its stake in shares of CalciMedica by 33.1% in the 2nd quarter. Cetera Investment Advisers now owns 36,385 shares of the company's stock valued at $58,000 after buying an additional 9,045 shares during the period. Finally, Sound View Wealth Advisors Group LLC acquired a new position in shares of CalciMedica during the second quarter worth about $32,000.</p>
<div class="lb-trans"><p>大型投資者最近調整了對該股票的持有。Stonehage Fleming Financial Services Holdings Ltd 在第三季度購買了價值 165,000 美元的 CalciMedica 新頭寸。Meritage Portfolio Management 在第三季度將其在 CalciMedica 的持股增加了 33.8%。Meritage Portfolio Management 目前擁有 61,539 股該公司的股票，價值 189,000 美元，此前在此期間又購買了 15,539 股。Sheets Smith Investment Management 在第三季度收購了價值約 157,000 美元的 CalciMedica 新股份。Cetera Investment Advisers 在第二季度將其在 CalciMedica 的股份增加了 33.1%。Cetera Investment Advisers 目前擁有 36,385 股該公司的股票，價值 58,000 美元，此前在此期間又購買了 9,045 股。最後，Sound View Wealth Advisors Group LLC 在第二季度收購了價值約 32,000 美元的 CalciMedica 新頭寸。</p>
</div><h2>CalciMedica Company Profile</h2>
<div class="lb-trans"><h2>CalciMedica 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>CalciMedica, Inc NASDAQ: CALC is a clinical-stage biopharmaceutical company focused on developing therapies that modulate calcium-mediated inflammatory pathways. Headquartered in Northbrook, Illinois, the company applies proprietary ion channel technology to address severe inflammatory disorders driven by dysregulated immune responses.</p>
<div class="lb-trans"><p>CalciMedica, Inc.（納斯達克代碼：CALC）是一家臨牀階段的生物製藥公司，專注於開發調節鈣介導的炎症通路的療法。公司總部位於伊利諾伊州北布魯克，應用專有的離子通道技術來應對由免疫反應失調引起的嚴重炎症疾病。</p>
</div><p>The company's lead product candidate, Auxora™, is a selective inhibitor of calcium release-activated calcium (CRAC) channels. Auxora is being evaluated in clinical trials for the treatment of acute pancreatitis associated with systemic inflammatory response syndrome (SIRS) and acute respiratory distress syndrome (ARDS) in patients with severe pulmonary conditions, including COVID-19 pneumonia.</p>
<div class="lb-trans"><p>該公司的主要產品候選藥物 Auxora™是一種選擇性鈣釋放激活鈣（CRAC）通道抑制劑。Auxora 正在臨牀試驗中評估用於治療與全身性炎症反應綜合症（SIRS）和急性呼吸窘迫綜合症（ARDS）相關的急性胰腺炎，適用於包括 COVID-19 肺炎在內的嚴重肺部疾病患者。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than CalciMedica</li>
<li>Do not delete, read immediately</li>
<li>The Crash Has Already Started (Most Just Don’t See It Yet)</li>
<li>ALERT: Drop these 5 stocks before January 2026!</li>
<li>[No Brainer Gold Play]: “Show me a better investment.”</li>
<li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 CalciMedica 更好</li>
<li>請勿刪除，立即閲讀</li>
<li>崩盤已經開始（大多數人只是看不見而已）</li>
<li>警報：在 2026 年 1 月之前拋售這五隻股票！</li>
<li>[無腦黃金投資]：“給我一個更好的投資。”</li>
<li>投資者警報：微型 “3 美元人工智能奇蹟股票” 即將爆發</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞警報由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in CalciMedica Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 CalciMedica 嗎？</h2>
</div><p>Before you consider CalciMedica, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮投資 CalciMedica 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CalciMedica wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 CalciMedica 並不在名單上。</p>
</div><p>While CalciMedica currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 CalciMedica 目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

CalciMedica (NASDAQ:CALC) 股價下跌 2.1% - 現在是賣出的時候嗎？